Chlodantane: the development record

From experimental adaptogen to later research

1. 1989 filing / 1996 publication. The original certificate describes Chlodantane and ADK-918 in environmental-resistance research. Patent claims are part of the development history.
2. 1995. Krasnykh’s dedicated pharmacokinetics dissertation is identified in catalogue metadata. Its complete text remains an acquisition target.
3. 1999. Morozov and colleagues summarized a 329-compound adamantane screening program and described Chlodantane as a rapid-action adaptogen in animal research. That screening total does not establish what the ADK numbering system meant.
4. 2001. Bugaeva’s toxicology author abstract reports submission of preclinical dossiers to the Pharmacological Committee and recommendation for clinical investigation. The committee decision itself has not been recovered. Kuzubova’s reproductive-study dissertation also discusses anticipated clinical use, while its experiments concern animals.
5. 2004–2006. A rat reproductive-function paper, tissue-distribution publication and Safronenko dissertation show continuing preclinical investigation. These sources should not be counted as independent programs without checking their shared experiments.
6. 2009. An industrial-safety author abstract states that Chlodantane was undergoing clinical trials. The reviewed introduction supplies no human cohort, protocol or outcomes.
7. 2016–2019. A formulation patent, filed in 2016 and published in 2019, revisits performance under high and low temperatures. Its intended occupational applications are not proof of administration to service members.

Clinical-trial announcement: original wording and translation

The announcement is dated 21 February 2023; this source review was updated on 1 November 2026. It describes prior clinical development, rather than recruitment for a new trial.

«прошел необходимые этапы клинических исследований»

English translation: “completed the necessary stages of clinical studies.”

Read the original Sirius University announcement ↗

On 21 February 2023, Sirius University reported cage-amide antiviral research and stated that Chlodantane had completed the necessary stages of clinical studies. The release also describes it as having the status of a medicinal product; an institutional description is not independent verification of a marketing authorization. This is a direct institutional statement and belongs in the historical record.

The release does not identify a primary human-trial publication, registration or protocol number, participant count, clinical site, treatment group or outcome. The linked research context concerns laboratory antiviral experiments. It cannot supply the missing clinical evidence.

The current conclusion is that clinical testing was reported in historical and institutional sources, while an independently appraisable human-trial report has not been located. This does not prove that testing never occurred, and the institutional statements alone do not establish efficacy or safety.

Later publications and their significance

The cage-amide paper

Mozhaitsev and colleagues, Viruses 2023;15(1):29 was published online on 21 December 2022. DOI: 10.3390/v15010029. It documents cell-culture antiviral research and computational modelling across a cage-amide family. Its leading compound is distinct from Chlodantane. A proposed target from modelling is different from demonstrated target binding, and laboratory activity is different from a clinical treatment result.

This publication documents the research behind the institutional news context; it does not resolve the historical human-testing claim. The original full-text XML was reviewed. Experimental synthesis and virology procedures are not reproduced here.

The 2025 gram-scale synthesis paper

Cicco, Yousaf, Vitale, Perna and Capriati, RSC Sustainability 2025;3:4079–4086. DOI: 10.1039/D5SU00489F. First published 15 July 2025. Chlodantane served as a gram-scale demonstration in a chemical-method study evaluating reusable reaction media and process sustainability.

Its historical importance is evidence of continuing interest in Chlodantane as a defined chemical research example. Chemical characterization and scale-up do not establish a clinical effect. The paper’s ADK-919 label differs from the established historical ADK-910 designation; the discrepancy is retained rather than silently creating a new alias. The full citation and PDF reference are preserved in the bibliography.

The documents that could resolve the history

• The Pharmacological Committee decision and ADK-910 development dossier, including authorized investigators and sites.
• A primary human-study report giving participant numbers, dates, preparation, methods, clinical outcomes and adverse events.
• The complete Krasnykh and Safronenko pharmacokinetic dissertations and the 2005 paper’s original tissue-exposure tables.
• The relevant passages in Morozov, Petrov and Sergeeva’s 2001 Pharmacology of Adamantanes, with the original references behind occupational-use statements.
• Clarification of the 2025 paper’s ADK code and reconciliation of the 2004 paper’s conflicting long-course duration and group denominators.

Checked sources include the named author-abstract transcriptions, original institutional release, publisher/indexed chemistry records and the cage-amide full-text XML. Name-variant searches did not identify a primary Chlodantane human cohort. This is a scoped literature search, not an exhaustive review of every historical archive or regulatory registry.